Track record
Every buy, sell, and watch call I've published — scored against XBI, the biotech index.
As of Oct 9, 2026 · hypothetical editorial record, not investment advice
How to read this page
- Buy
- A buy call I published — Core = higher conviction.
- Spec buy
- A speculative buy — higher risk, smaller-size idea.
- Avoid
- A call to stay away — scored by the loss it sidestepped.
- Buy▵
- Conviction changed since the call opened — e.g. opened as a Spec buy, now a Buy. The badge shows today's conviction; the linked post is the opening call. Hover the badge for the date it changed.
- Entry
- The first closing price after I published the call — if I posted after the 4pm ET close, that's the next session's close, since it's the first price you could actually have traded at.
- Now
- The latest available closing price — on a closed call, the price it exited at, not today's price.
- Return
- Percent change from Entry to Now. Read it with the call type: on a buy, higher is better; on an avoid it is the stock's move, so a big positive number means the avoid was wrong. vs XBI is the column that scores every call the same way.
- vs XBI
- XBI is the biotech index ETF. This is Return minus XBI's return over the same dates — the value added beyond just buying the index. For avoids, the loss saved vs holding XBI.
- Dates
- Opened and Closed are the market sessions the call was priced at, which is usually the session after the post — a call published after the 4pm ET bell on a Friday prices on Monday. Hover a date to see which post it came from.
- Open / Closed
- Open = still live. Closed = realized; the return runs to the first close after I flipped the call. Where a buyout settled at a known cash price, I use that instead.
Top buy calls
| Call | Buy | Now | Return | vs XBI |
|---|---|---|---|---|
| ETON Eton Pharmaceuticals Buy | $18.22 | $55.21 | +203% | +181.7 |
| IBRX ImmunityBio Buy | $3.95 | $10.51 | +166.1% | +142.3 |
| SYRE Spyre Therapeutics Buy | $33.47 | $85.69 | +156% | +127.5 |
| DFTX Definium Therapeutics Buy | $15.02 | $36.90 | +145.7% | +124.4 |
| DRTS Alpha Tau Medical Spec buy | $5.90 | $14.41 | +144.2% | +122.6 |
| CAPR Capricor Therapeutics Spec buy | $4.17 | $7.83 | +87.8% | +86.5 |
| HELP Helus Pharma Spec buy | $6.61 | $11.80 | +78.5% | +81.3 |
| TTRX Turn Therapeutics Spec buy | $6.42 | $12.00 | +86.9% | +66.6 |
| ABSI Absci Buy | $5.90 | $10.16 | +72.2% | +58.1 |
| XERS Xeris Biopharma Spec buy | $7.93 | $10.48 | +32.2% | +34.4 |
What I told you to avoid
| Call | Since | Stock | Saved vs XBI |
|---|---|---|---|
| RVPH Reviva Pharmaceuticals Avoid | Jan 26, 2026 | -91.7% | +112.1 |
| LGVN Longeveron Avoid | May 11, 2026 | -70.4% | +84.5 |
| APVO Aptevo Therapeutics Avoid | Jun 16, 2026 | -60.6% | +74.2 |
| NRSN NeuroSense Therapeutics Avoid | Jul 13, 2026 | -74.9% | +73.9 |
| ACTU Actuate Therapeutics Avoid | Jul 20, 2026 | -56.4% | +58.3 |
| MRKR Marker Therapeutics Avoid | Mar 16, 2026 | -31.2% | +55.3 |
| VNDA Vanda Pharmaceuticals Avoid | Feb 17, 2026 | -26.3% | +49.7 |
| OTLK Outlook Therapeutics Avoid | Jul 27, 2026 | -43.8% | +45.9 |
Calls that paid off
Buy calls I closed in the green — including takeouts. Entry → exit, realized.
| Call | Bought | Exited | Return | vs XBI |
|---|---|---|---|---|
| FBRX Forte Biosciences Acquired | Apr 6, 2026 | Jul 28, 2026 | +189.9% | +173.6 |
| CRNX Crinetics Pharmaceuticals Acquired | Apr 2, 2026 | Jul 7, 2026 | +124.4% | +97.3 |
| ATAI Atai Beckley Acquired | Dec 24, 2025 | Jul 17, 2026 | +72.3% | +50.2 |
| APGE Apogee Therapeutics Acquired | May 5, 2026 | Jun 23, 2026 | +59.5% | +49.6 |
| CNTA Centessa Pharmaceuticals plc Acquired | Mar 16, 2026 | Jun 23, 2026 | +43.2% | +24.4 |
| QURE uniQure Spec buy | Jun 18, 2026 | Jun 23, 2026 | +5.9% | +1.4 |
| ENTA Enanta Pharmaceuticals Buy | Feb 17, 2026 | Jul 6, 2026 | +4.7% | -24.5 |
Every call
| Call | Entry | Now | Return | vs XBI | Status | Opened |
|---|---|---|---|---|---|---|
| ETON Eton Pharmaceuticals Buy | $18.22 | $55.21 | +203% | +181.7 | Open | Feb 19, 2026 |
| FBRX Forte Biosciences Buy▵ | $26.44 | $76.65 | +189.9% | +173.6 | Closed Jul 28, 2026 | Apr 6, 2026 |
| IBRX ImmunityBio Buy▵ | $3.95 | $10.51 | +166.1% | +142.3 | Open | Jan 15, 2026 |
| SYRE Spyre Therapeutics Buy | $33.47 | $85.69 | +156% | +127.5 | Open | Dec 18, 2025 |
| DFTX Definium Therapeutics Buy | $15.02 | $36.90 | +145.7% | +124.4 | Open | Jan 14, 2026 |
| DRTS Alpha Tau Medical Spec buy | $5.90 | $14.41 | +144.2% | +122.6 | Open | Jan 7, 2026 |
| RVPH Reviva Pharmaceuticals Avoid | $6.04 | $0.50 | -91.7% | +112.1 | Open | Jan 26, 2026 |
| CRNX Crinetics Pharmaceuticals Buy | $37.23 | $83.53 | +124.4% | +97.3 | Closed Jul 7, 2026 | Apr 2, 2026 |
| GOSS Gossamer Bio Avoid | $34.29 | $14.00 | -59.2% | +88.9 | Closed Aug 24, 2026 | Mar 2, 2026 |
| CAPR Capricor Therapeutics Spec buy | $4.17 | $7.83 | +87.8% | +86.5 | Open | Aug 4, 2026 |
| LGVN Longeveron Avoid | $8.38 | $2.48 | -70.4% | +84.5 | Open | May 11, 2026 |
| HELP Helus Pharma Spec buy | $6.61 | $11.80 | +78.5% | +81.3 | Open | Jun 30, 2026 |
| APVO Aptevo Therapeutics Avoid | $4.54 | $1.79 | -60.6% | +74.2 | Open | Jun 16, 2026 |
| NRSN NeuroSense Therapeutics Avoid | $14.60 | $3.66 | -74.9% | +73.9 | Open | Jul 13, 2026 |
| TTRX Turn Therapeutics Spec buy | $6.42 | $12.00 | +86.9% | +66.6 | Open | Jun 2, 2026 |
| ACTU Actuate Therapeutics Avoid | $6.49 | $2.89 | -55.5% | +62.2 | Closed May 12, 2026 | Jan 7, 2026 |
| ACTU Actuate Therapeutics Avoid | $1.40 | $0.61 | -56.4% | +58.3 | Open | Jul 20, 2026 |
| ABSI Absci Buy▵ | $5.90 | $10.16 | +72.2% | +58.1 | Open | May 8, 2026 |
| MRKR Marker Therapeutics Avoid | $1.41 | $0.97 | -31.2% | +55.3 | Open | Mar 16, 2026 |
| KAPA Kairos Pharma Avoid | $2.17 | $0.87 | -59.9% | +53.7 | Closed Oct 7, 2026 | Aug 18, 2026 |
| ATAI Atai Beckley Spec buy | $4.19 | $7.22 | +72.3% | +50.2 | Closed Jul 17, 2026 | Dec 24, 2025 |
| VNDA Vanda Pharmaceuticals Avoid | $6.20 | $4.57 | -26.3% | +49.7 | Open | Feb 17, 2026 |
| APGE Apogee Therapeutics Buy | $83.29 | $132.88 | +59.5% | +49.6 | Closed Jun 23, 2026 | May 5, 2026 |
| OTLK Outlook Therapeutics Avoid | $1.06 | $0.60 | -43.8% | +45.9 | Open | Jul 27, 2026 |
| EVMN Evommune Avoid | $13.29 | $6.92 | -47.9% | +45.5 | Closed Oct 2, 2026 | Jun 30, 2026 |
| CING Cingulate Avoid | $5.84 | $5.09 | -12.8% | +45.4 | Closed Aug 14, 2026 | Mar 30, 2026 |
| PCSA Processa Pharmaceuticals Avoid | $2.87 | $2.04 | -28.9% | +43.6 | Closed Jul 30, 2026 | Apr 13, 2026 |
| PHIO Phio Pharmaceuticals Avoid | $1.32 | $0.98 | -25.8% | +38.5 | Open | Apr 15, 2026 |
| ELTX Elicio Therapeutics Avoid | $3.29 | $1.89 | -42.6% | +38.3 | Open | Jul 6, 2026 |
| XERS Xeris Biopharma Spec buy | $7.93 | $10.48 | +32.2% | +34.4 | Open | Aug 7, 2026 |
| REPL Replimune Group Buy▵ | $9.00 | $13.42 | +49.1% | +33.9 | Open | Jun 1, 2026 |
| CMPS COMPASS Pathways Buy | $7.85 | $12.00 | +52.9% | +31.8 | Open | Feb 23, 2026 |
| IXHL Incannex Healthcare Avoid | $3.31 | $3.10 | -6.3% | +30.4 | Open | Mar 16, 2026 |
| CRBU Caribou Biosciences Avoid | $0.62 | $0.46 | -25.4% | +27.8 | Open | Oct 7, 2026 |
| VSTM Verastem Spec buy | $6.74 | $8.38 | +24.3% | +26.6 | Open | Aug 7, 2026 |
| CNTA Centessa Pharmaceuticals plc Buy | $28.29 | $40.50 | +43.2% | +24.4 | Closed Jun 23, 2026 | Mar 16, 2026 |
| ONCY Oncolytics Biotech Avoid | $0.77 | $0.56 | -27.3% | +24.4 | Open | Sep 17, 2026 |
| IRD Opus Genetics Spec buy | $3.71 | $4.65 | +25.3% | +24.1 | Open | Aug 4, 2026 |
| NRIX Nurix Therapeutics Buy | $15.91 | $22.35 | +40.5% | +24 | Open | Apr 13, 2026 |
| PMVP PMV Pharmaceuticals Spec buy | $1.29 | $1.52 | +17.8% | +23.7 | Open | Sep 1, 2026 |
| ADAG Adagene Spec buy | $1.84 | $2.76 | +50% | +23.5 | Open | Jan 2, 2026 |
| ALDX Aldeyra Therapeutics Avoid | $1.23 | $0.92 | -25.5% | +23 | Open | Sep 30, 2026 |
| EXEL Exelixis Spec buy▵ | $41.36 | $59.86 | +44.7% | +21.5 | Open | Jan 30, 2026 |
| MBRX Moleculin Biotech Avoid | $0.57 | $0.44 | -22% | +20.6 | Open | Sep 24, 2026 |
| IVVD Invivyd Avoid | $0.96 | $0.72 | -25.2% | +20.2 | Open | Sep 22, 2026 |
| VOR Vor Biopharma Spec buy | $14.63 | $19.90 | +36% | +18.4 | Open | May 15, 2026 |
| TVTX Travere Therapeutics Buy | $40.29 | $52.13 | +29.4% | +17.8 | Open | Apr 20, 2026 |
| MDNAF Medicenna Therapeutics Avoid | $0.40 | $0.32 | -20% | +17.6 | Closed May 20, 2026 | May 14, 2026 |
| ORKA Oruka Therapeutics Buy | $63.18 | $82.11 | +30% | +16.8 | Open | May 13, 2026 |
| OVID Ovid Therapeutics Spec buy | $1.81 | $2.46 | +35.9% | +16.3 | Open | Jan 27, 2026 |
| ARDX Ardelyx Avoid | $4.00 | $3.28 | -18% | +15.7 | Open | Aug 7, 2026 |
| HELP Helus Pharma Avoid | $5.52 | $4.32 | -21.7% | +15.2 | Closed Mar 30, 2026 | Mar 9, 2026 |
| CMPX Compass Therapeutics Avoid | $1.17 | $0.99 | -15.1% | +14.2 | Open | Sep 23, 2026 |
| CMMB Chemomab Therapeutics Avoid | $1.64 | $1.38 | -15.9% | +14 | Open | Sep 28, 2026 |
| UNCY Unicycive Therapeutics Avoid | $5.13 | $4.70 | -8.5% | +13.3 | Closed Sep 30, 2026 | Jul 27, 2026 |
| XNCR Xencor Spec buy | $21.49 | $24.63 | +14.6% | +13.1 | Open | Jul 30, 2026 |
| KYMR Kymera Therapeutics Buy | $87.35 | $112.40 | +28.7% | +12 | Open | Apr 9, 2026 |
| ZYME Zymeworks Buy▵ | $23.54 | $25.79 | +9.6% | +11.8 | Open | Aug 7, 2026 |
| GHRS GH Research Buy | $15.75 | $21.11 | +34% | +11.3 | Open | Jan 20, 2026 |
| CYDY CytoDyn Avoid | $0.37 | $0.32 | -13.5% | +11.1 | Closed Apr 27, 2026 | Apr 21, 2026 |
| JANX Janux Therapeutics Buy | $14.11 | $18.39 | +30.3% | +11 | Open | Apr 29, 2026 |
| PYPD PolyPid Spec buy | $4.78 | $5.07 | +6.1% | +8 | Open | Aug 13, 2026 |
| CGEM Cullinan Therapeutics Buy▵ | $12.57 | $15.53 | +23.5% | +6.7 | Open | Jan 22, 2026 |
| VIR Vir Biotechnology Buy | $8.99 | $11.70 | +30.1% | +6.1 | Open | Mar 25, 2026 |
| CLYM Climb Bio Buy▵ | $8.78 | $11.00 | +25.3% | +6 | Open | Apr 29, 2026 |
| BEAM Beam Therapeutics Spec buy | $25.18 | $25.70 | +2.1% | +5.6 | Open | Sep 9, 2026 |
| PCVX Vaxcyte Buy | $66.70 | $71.38 | +7% | +5.1 | Open | Oct 6, 2026 |
| PTN Palatin Technologies Avoid | $9.12 | $8.60 | -5.7% | +3.8 | Open | Sep 29, 2026 |
| GANX Gain Therapeutics Avoid | $1.71 | $1.64 | -4.1% | +3.7 | Open | Oct 2, 2026 |
| CYDY CytoDyn Avoid | $0.22 | $0.20 | -9.1% | +3.2 | Open | Sep 1, 2026 |
| OMER Omeros Buy | $15.71 | $19.83 | +26.2% | +3.2 | Open | Dec 26, 2025 |
| SPRB Spruce Biosciences Buy▵ | $41.60 | $44.05 | +5.9% | +3.2 | Open | Jul 28, 2026 |
| PTGX Protagonist Therapeutics Buy | $147.75 | $143.73 | -2.7% | +2.7 | Open | Aug 31, 2026 |
| CRVO CervoMed Avoid | $2.44 | $2.86 | +17.2% | +2 | Closed Aug 10, 2026 | Jun 11, 2026 |
| GRCE Grace Therapeutics Avoid | $2.16 | $2.10 | -2.8% | +1.4 | Closed Apr 28, 2026 | Apr 27, 2026 |
| QURE uniQure Spec buy | $46.29 | $49.04 | +5.9% | +1.4 | Closed Jun 23, 2026 | Jun 18, 2026 |
| SION Sionna Therapeutics Avoid | $5.10 | $4.90 | -3.9% | +1.2 | Open | Aug 11, 2026 |
| FHTX Foghorn Therapeutics Avoid | $2.02 | $2.00 | -1% | +0.6 | Open | Oct 2, 2026 |
| BCTX BriaCell Therapeutics Avoid | $3.31 | $3.91 | +18.1% | +0.3 | Open | Jun 3, 2026 |
| CRDL Cardiol Therapeutics Spec buy | $1.02 | $1.23 | +20.6% | -0.9 | Open | Mar 2, 2026 |
| GRCE Grace Therapeutics Spec buy | $2.12 | $2.08 | -1.9% | -1.4 | Open | Aug 6, 2026 |
| CGON CG Oncology Buy | $53.81 | $63.82 | +18.6% | -1.5 | Open | Jan 23, 2026 |
| CBIO Crescent Biopharma Buy | $15.11 | $14.91 | -1.3% | -2.5 | Open | Jul 16, 2026 |
| KURA Kura Oncology Buy | $9.22 | $10.60 | +15% | -2.7 | Open | May 15, 2026 |
| IMVT Immunovant Buy | $26.08 | $30.47 | +16.8% | -3.9 | Open | Feb 2, 2026 |
| ENTA Enanta Pharmaceuticals Spec buy | $13.50 | $12.50 | -7.4% | -4.7 | Open | Aug 12, 2026 |
| ZBIO Zenas BioPharma Spec buy | $29.51 | $27.26 | -7.6% | -5.3 | Open | Aug 14, 2026 |
| TLSA Tiziana Life Sciences Avoid | $1.11 | $1.19 | +7.2% | -5.3 | Open | Oct 6, 2026 |
| PEPG PepGen Spec buy | $2.85 | $2.62 | -8.1% | -5.8 | Open | Aug 7, 2026 |
| KPRX Kiora Pharmaceuticals Spec buy | $2.32 | $2.54 | +9.5% | -6.1 | Open | Apr 27, 2026 |
| LEGN Legend Biotech Spec buy | $20.65 | $18.62 | -9.8% | -6.3 | Open | Aug 12, 2026 |
| IMCR Immunocore Spec buy | $32.00 | $29.39 | -8.2% | -6.3 | Open | Sep 18, 2026 |
| TENX Tenax Therapeutics Avoid | $1.62 | $1.80 | +11.1% | -7.7 | Closed Sep 1, 2026 | Aug 11, 2026 |
| AUTL Autolus Therapeutics Spec buy | $1.95 | $1.81 | -7.2% | -8.4 | Open | Aug 4, 2026 |
| ARVN Arvinas Spec buy | $8.40 | $7.64 | -9% | -9.5 | Open | Aug 5, 2026 |
| BLTE Belite Bio Spec buy | $178.94 | $154.49 | -13.7% | -10.1 | Open | Aug 12, 2026 |
| SNDX Syndax Pharmaceuticals Buy | $20.56 | $16.99 | -17.4% | -11.2 | Open | Sep 4, 2026 |
| RNAC Cartesian Therapeutics Buy | $6.93 | $7.05 | +1.8% | -12.6 | Open | May 27, 2026 |
| SMMT Summit Therapeutics Buy | $15.94 | $17.59 | +10.4% | -12.9 | Open | Feb 20, 2026 |
| NGNE Neurogene Spec buy | $31.45 | $26.40 | -16.1% | -13.2 | Open | Jun 30, 2026 |
| ADMA Adma Biologics Avoid | $9.16 | $10.06 | +9.8% | -13.7 | Closed Aug 6, 2026 | Jul 6, 2026 |
| PRQR ProQR Therapeutics Spec buy | $1.94 | $1.63 | -16% | -14 | Open | Sep 10, 2026 |
| LGVN Longeveron Spec buy | $8.88 | $8.38 | -5.6% | -14.4 | Closed May 11, 2026 | Mar 16, 2026 |
| CHRS Coherus Oncology Spec buy | $1.26 | $1.07 | -15.4% | -14.9 | Open | Aug 6, 2026 |
| SGMT Sagimet Biosciences Spec buy | $8.75 | $8.93 | +2.1% | -15.2 | Open | Apr 28, 2026 |
| BCTX BriaCell Therapeutics Spec buy | $4.47 | $3.76 | -15.9% | -15.6 | Closed Feb 23, 2026 | Feb 2, 2026 |
| CUE Cue Biopharma Buy▵ | $26.91 | $27.66 | +2.8% | -15.7 | Open | Jun 3, 2026 |
| SLDB Solid Biosciences Spec buy | $8.39 | $6.87 | -18.1% | -15.8 | Open | Aug 7, 2026 |
| INBX Inhibrx Biosciences Spec buy | $122.26 | $95.01 | -22.3% | -15.8 | Open | Sep 3, 2026 |
| RCUS Arcus Biosciences Spec buy | $24.69 | $24.41 | -1.1% | -16.4 | Open | Jun 4, 2026 |
| NVCT Nuvectis Pharma Spec buy | $24.48 | $21.12 | -13.7% | -16.4 | Open | Jun 24, 2026 |
| MDNAF Medicenna Therapeutics Spec buy | $0.32 | $0.32 | -1.9% | -17.3 | Open | May 26, 2026 |
| AMLX Amylyx Pharmaceuticals Spec buy | $38.60 | $28.14 | -27.1% | -17.8 | Open | Aug 19, 2026 |
| HELP Helus Pharma Spec buy | $6.73 | $5.52 | -18% | -18.1 | Closed Mar 9, 2026 | Feb 23, 2026 |
| NTLA Intellia Therapeutics Spec buy▵ | $13.20 | $13.07 | -1% | -18.2 | Open | Apr 28, 2026 |
| TNGX Tango Therapeutics Buy▵ | $24.87 | $23.81 | -4.3% | -18.3 | Open | May 14, 2026 |
| ALLO Allogene Therapeutics Spec buy | $2.25 | $2.07 | -8% | -18.5 | Closed Jun 23, 2026 | Apr 27, 2026 |
| ALLO Allogene Therapeutics Spec buy | $1.79 | $1.46 | -18.4% | -19.6 | Open | Jul 16, 2026 |
| SABS SAB Biotherapeutics Spec buy | $3.67 | $2.98 | -18.7% | -19.9 | Open | Jul 16, 2026 |
| GERN Geron Spec buy | $1.57 | $1.23 | -21.7% | -21.2 | Open | Aug 6, 2026 |
| NRXP NRX Pharmaceuticals Spec buy | $3.03 | $2.85 | -5.9% | -21.5 | Open | Apr 27, 2026 |
| ARTV Artiva Biotherapeutics Spec buy | $7.27 | $6.94 | -4.5% | -21.6 | Open | Jun 9, 2026 |
| BMEA Biomea Fusion Spec buy | $1.53 | $1.49 | -2.6% | -21.6 | Closed Sep 24, 2026 | Apr 28, 2026 |
| AKTS Aktis Oncology Buy▵ | $19.73 | $18.15 | -8% | -22 | Open | May 12, 2026 |
| QNRX Quoin Pharmaceuticals Spec buy | $6.22 | $4.50 | -27.7% | -22.3 | Open | Aug 31, 2026 |
| DYN Dyne Therapeutics Buy | $16.58 | $16.64 | +0.4% | -22.4 | Open | Jan 20, 2026 |
| VRCA Verrica Pharmaceuticals Spec buy | $5.69 | $4.11 | -27.8% | -22.5 | Open | Aug 28, 2026 |
| VERA Vera Therapeutics Buy | $31.27 | $29.88 | -4.4% | -22.9 | Open | Jun 3, 2026 |
| ARTV Artiva Biotherapeutics Spec buy | $10.60 | $7.84 | -26% | -23.7 | Closed May 20, 2026 | May 11, 2026 |
| ZNTL Zentalis Pharmaceuticals Spec buy | $3.83 | $2.64 | -31% | -23.8 | Open | Aug 21, 2026 |
| LENZ LENZ Therapeutics Spec buy | $5.04 | $3.65 | -27.7% | -24.2 | Open | Aug 12, 2026 |
| ENTA Enanta Pharmaceuticals Buy▵ | $13.86 | $14.51 | +4.7% | -24.5 | Closed Jul 6, 2026 | Feb 17, 2026 |
| ERAS Erasca Spec buy | $11.56 | $9.11 | -21.2% | -24.6 | Closed Apr 29, 2026 | Feb 11, 2026 |
| SRPT Sarepta Therapeutics Spec buy | $17.79 | $17.85 | +0.3% | -24.8 | Open | Feb 13, 2026 |
| CLDX Celldex Therapeutics Buy | $33.86 | $29.89 | -11.7% | -25.2 | Open | Apr 16, 2026 |
| IMMX Immix Biopharma Buy | $10.66 | $9.46 | -11.3% | -25.2 | Open | May 12, 2026 |
| ACRV Acrivon Therapeutics Buy | $1.93 | $1.91 | -1% | -25.3 | Open | Jan 8, 2026 |
| NBP NovaBridge Biosciences Spec buy | $1.95 | $1.40 | -28.5% | -25.6 | Open | Jun 30, 2026 |
| FBIO Fortress Biotech Spec buy | $2.30 | $2.03 | -11.7% | -26.3 | Closed Oct 2, 2026 | May 14, 2026 |
| PCSA Processa Pharmaceuticals Spec buy | $2.04 | $1.52 | -25.5% | -27 | Open | Jul 30, 2026 |
| CCCC C4 Therapeutics Buy▵ | $3.68 | $3.16 | -14.1% | -27.3 | Open | May 13, 2026 |
| COGT Cogent Biosciences Buy | $37.00 | $31.00 | -16.2% | -27.8 | Open | Apr 20, 2026 |
| CRVS Corvus Pharmaceuticals Buy | $11.50 | $10.52 | -8.5% | -29.8 | Open | May 19, 2026 |
| SANA Sana Biotechnology Spec buy | $3.26 | $2.79 | -14.4% | -30 | Open | Apr 27, 2026 |
| CATX Perspective Therapeutics Buy▵ | $2.73 | $2.66 | -2.6% | -30.5 | Open | Jan 5, 2026 |
| AGMB Agomab Therapeutics Spec buy | $12.68 | $9.08 | -28.4% | -31.1 | Open | Jun 24, 2026 |
| CBIO Crescent Biopharma Buy | $18.52 | $15.67 | -15.4% | -31.3 | Closed Jul 15, 2026 | May 11, 2026 |
| OCS Oculis Holding Spec buy | $11.99 | $8.34 | -30.4% | -31.7 | Open | Aug 4, 2026 |
| MPLT MapLight Therapeutics Spec buy | $12.92 | $8.83 | -31.7% | -32.2 | Open | Aug 5, 2026 |
| ACRS Aclaris Therapeutics Buy | $4.47 | $3.83 | -14.3% | -33.6 | Open | Apr 29, 2026 |
| RYTM Rhythm Pharmaceuticals Buy | $102.59 | $90.78 | -11.5% | -34.2 | Open | Jan 20, 2026 |
| ARVN Arvinas Spec buy | $10.78 | $8.14 | -24.5% | -34.6 | Closed Jun 23, 2026 | May 4, 2026 |
| ELTX Elicio Therapeutics Avoid | $2.76 | $3.85 | +39.5% | -35.6 | Closed Jun 18, 2026 | Jun 16, 2026 |
| PMN ProMIS Neurosciences Spec buy | $14.06 | $9.61 | -31.7% | -35.6 | Open | Jul 29, 2026 |
| MAIA MAIA Biotechnology Spec buy | $1.31 | $1.22 | -6.9% | -36.3 | Open | Mar 30, 2026 |
| VTVT vTv Therapeutics Spec buy | $36.41 | $31.18 | -14.4% | -37.1 | Open | Feb 4, 2026 |
| RARE Ultragenyx Pharmaceutical Buy▵ | $26.86 | $15.48 | -42.4% | -38.8 | Open | Aug 12, 2026 |
| JBIO Jade Biosciences Spec buy | $17.75 | $14.39 | -18.9% | -39.3 | Open | Jun 2, 2026 |
| CGTX Cognition Therapeutics Spec buy | $1.08 | $0.88 | -18.8% | -39.8 | Open | Mar 9, 2026 |
| RCKT Rocket Pharmaceuticals Spec buy | $3.59 | $2.56 | -28.7% | -42.8 | Open | May 11, 2026 |
| ANAB AnaptysBio Spec buy | $65.58 | $45.95 | -29.9% | -43.9 | Open | May 12, 2026 |
| KYTX Kyverna Therapeutics Buy▵ | $8.99 | $6.39 | -28.9% | -44.5 | Open | Apr 27, 2026 |
| VKTX Viking Therapeutics Buy | $36.41 | $28.51 | -21.7% | -44.8 | Open | Dec 23, 2025 |
| AKBA Akebia Therapeutics Spec buy | $1.16 | $0.80 | -30.9% | -45.1 | Open | May 8, 2026 |
| GLSI Greenwich LifeSciences Spec buy | $22.25 | $16.53 | -25.7% | -45.3 | Open | Jun 5, 2026 |
| TSHA Taysha Gene Therapies Buy | $6.46 | $4.49 | -30.5% | -46.1 | Open | Apr 27, 2026 |
| ABOS Acumen Pharmaceuticals Spec buy▵ | $2.71 | $2.14 | -21% | -47.5 | Open | Mar 23, 2026 |
| BBOT BridgeBio Oncology Therapeutics Spec buy | $6.75 | $3.31 | -51% | -47.5 | Open | Sep 9, 2026 |
| GRCE Grace Therapeutics Spec buy▵ | $3.83 | $2.16 | -43.6% | -47.7 | Closed Apr 27, 2026 | Jan 26, 2026 |
| CNTB Connect Biopharma Spec buy | $2.54 | $1.24 | -51.2% | -49.5 | Closed Sep 16, 2026 | Aug 13, 2026 |
| CLNN Clene Buy▵ | $5.18 | $3.86 | -25.5% | -49.6 | Open | Jan 12, 2026 |
| DBVT DBV Technologies Buy | $20.27 | $14.70 | -27.5% | -50 | Closed Jul 17, 2026 | Dec 22, 2025 |
| IPSC Century Therapeutics Spec buy | $2.21 | $1.47 | -33.5% | -50.5 | Open | Jun 9, 2026 |
| XENE Xenon Pharmaceuticals Buy | $57.40 | $36.44 | -36.5% | -51.7 | Open | May 4, 2026 |
| ATHE Alterity Therapeutics Buy | $4.73 | $3.12 | -34% | -51.9 | Open | May 1, 2026 |
| CYDY CytoDyn Spec buy | $0.32 | $0.22 | -31.2% | -54.1 | Closed Sep 1, 2026 | Apr 27, 2026 |
| GLUE Monte Rosa Therapeutics Buy | $17.50 | $10.30 | -41.1% | -54.4 | Open | Apr 14, 2026 |
| IMTX Immatics Buy | $10.45 | $7.43 | -28.9% | -55.4 | Open | Jan 2, 2026 |
| OCGN Ocugen Spec buy | $1.65 | $1.00 | -39.4% | -58 | Closed Sep 24, 2026 | Jan 22, 2026 |
| GPCR Structure Therapeutics Buy | $43.56 | $25.54 | -41.4% | -58.6 | Open | Apr 28, 2026 |
| CABA Cabaletta Bio Buy▵ | $3.31 | $1.93 | -41.7% | -59.4 | Open | May 15, 2026 |
| KTTA Pasithea Therapeutics Buy | $0.77 | $0.47 | -39.2% | -59.7 | Open | May 18, 2026 |
| INAB IN8bio Spec buy | $1.56 | $0.98 | -37.2% | -60.4 | Closed Aug 7, 2026 | Jun 2, 2026 |
| VRDN Viridian Therapeutics Buy | $29.17 | $18.66 | -36% | -63.4 | Open | Feb 5, 2026 |
| ALT Altimmune Buy▵ | $4.09 | $2.61 | -36.2% | -64.2 | Open | Jan 5, 2026 |
| IMRX Immuneering Spec buy▵ | $6.66 | $3.94 | -40.8% | -65.5 | Open | Dec 29, 2025 |
| CTMX CytomX Therapeutics Spec buy | $4.46 | $2.57 | -42.4% | -68.7 | Open | Mar 23, 2026 |
| GANX Gain Therapeutics Buy▵ | $3.19 | $1.71 | -46.4% | -69 | Closed Oct 2, 2026 | Dec 22, 2025 |
| LRMR Larimar Therapeutics Buy | $5.23 | $2.67 | -48.9% | -70.5 | Open | Mar 2, 2026 |
| NGEN NervGen Pharma Spec buy | $3.85 | $1.73 | -55.1% | -70.6 | Open | Apr 27, 2026 |
| STRO Sutro Biopharma Buy▵ | $33.59 | $14.27 | -57.5% | -73.1 | Open | Apr 27, 2026 |
| ADCT ADC Therapeutics Avoid | $1.01 | $1.73 | +71.3% | -73.6 | Closed Oct 9, 2026 | Aug 14, 2026 |
| BIOA BioAge Labs Buy | $15.34 | $6.34 | -58.7% | -79.1 | Open | May 18, 2026 |
| CRBU Caribou Biosciences Spec buy | $1.94 | $0.62 | -68.2% | -79.7 | Closed Oct 7, 2026 | May 8, 2026 |
| TARA Protara Therapeutics Spec buy | $7.43 | $2.75 | -62.9% | -84 | Open | Feb 23, 2026 |
| LXEO Lexeo Therapeutics Spec buy | $8.12 | $3.23 | -60.2% | -84.3 | Open | Jan 12, 2026 |
| MIST Milestone Pharmaceuticals Buy | $2.20 | $0.77 | -65.2% | -91.8 | Open | Dec 16, 2025 |
| EYPT EyePoint Buy | $13.34 | $3.40 | -74.5% | -92.4 | Open | May 1, 2026 |
| ERAS Erasca Avoid | $9.11 | $19.50 | +114.1% | -93.5 | Closed Jul 14, 2026 | Apr 29, 2026 |
| WVE Wave Life Sciences Buy | $13.44 | $3.46 | -74.3% | -98.8 | Open | Mar 3, 2026 |
| GUTS Fractyl Health Spec buy | $25.08 | $4.42 | -82.4% | -104 | Open | Jan 7, 2026 |
| QURE uniQure Avoid | $17.99 | $46.29 | +157.3% | -146.6 | Closed Jun 18, 2026 | Mar 9, 2026 |
| REPL Replimune Group Avoid | $1.70 | $9.00 | +429.4% | -428.3 | Closed Jun 1, 2026 | Apr 13, 2026 |
No calls match these filters.
On my watch list
- XFOR X4 Pharmaceuticals Watch
Mavorixafor is a real approved drug with a validated mechanism and serious institutional backing, but the CN infection thesis has no randomized evidence, the pivotal has been resized twice with a shifting power claim, and cash reaches the readout but not the launch.
-
Silevertinib has real CNS activity but is priced at cash with an unfunded pivotal trial, afatinib-grade toxicity at the tested dose, and a leading competitor already ten months into a comparable Phase 3.
- KROS Keros Therapeutics Watch
Keros trades below cash with a real Takeda royalty attached, but the cash is being spent on a lead asset with no disclosed human efficacy magnitudes and a poor class record in neuromuscular disease, making the discount a forecast of capital destruction rather than a mispricing.
- INSM Insmed Watch
CFO departure before the Q4 cohort data and no Q3 pre-announcement raises uncertainty, but ~20% multiple compression with no new data is approaching the entry profile; still prudent to wait for the October 29 print before upgrading.
- IMNM Immunome Watch
BMS royalty buyout removes one of three structural bear points and improves M&A appeal, making the setup more interesting near $21 with accumulation on weakness worth considering, but a confirmed upgrade likely needs the IM-1021 lymphoma readout.
- HROW Harrow Watch
TYRVAYA closing fixed the price and added Japan royalties but did not resolve the Novaliq non-compete conflict, and adds Q4 SG&A before TYRVAYA revenue arrives; the November Q3 print remains the key test.
- ANIX Anixa Biosciences Watch
Cohort 5 produced only one stable-disease result (not an objective response) and no DLTs, modestly de-risking safety but leaving efficacy and pharmacodynamics unproven; Watch List maintained pending RECIST-confirmed responses with denominators.
-
Bicycle's conjugates show real human proof of concept but the company has not demonstrated it will deploy its $7/share cash on anything the market will value, all big-pharma partners have left, and the lead pancreatic bet has no pancreatic efficacy data.
-
Pfizer has validated the KAT6 target but Prelude's key differentiator—KAT6A-selective degradation sparing marrow enough to combine with CDK4/6 inhibitors—has no human data, with preclinical evidence relying on racemate and tool-compound data; two dated events (Incyte option decision and first PRT13722 neutrophil counts) are needed before a position is warranted.
- NKTR Nektar Therapeutics Watch
The AA off-treatment durability data points the right way in 5/8 one-year responders but is built on n=8 with a weaker 36-week cohort, leaving the thesis intact but unproven; at ~$0.6B above cash the stock is approaching but not yet at a margin-of-safety entry point.
- LQDA Liquidia Watch
YUTREPIA's PAH business is real and profitable at a single-digit multiple, but the court has not yet defined the remedy scope, and damages plus a January 2027 trade-secret trial create too much uncertainty to buy before the judgment is public.
- QTTB Q32 Bio Watch
EADV delivered the JAK-naive/experienced split (mechanistically coherent) but the ITT mean remains withheld and responder-counting questions go unanswered, leaving the author short of speculative-buy conviction despite the enterprise value collapsing to ~$12M.
- KOD Kodiak Sciences Hold
Baker Bros. buying at post-data prices (~$90) strengthens conviction but does not change the stance; a financing is still needed and an offering-driven dip remains the better entry for new positions.
-
At ~$2.6B enterprise value the stock already prices a Phase 3 win built on 53 open-label patients whose nHCM symptom gain sits inside the placebo response of two randomized trials; randomized efficacy data won't exist until ~2029.
-
TX2100 Phase 1a clean safety de-risks the HHT lottery ticket on safety and target engagement, but APEX remains the binary and the PVR→6MWD translation question is unchanged.
- SCYX Scynexis Watch
BARDA's up-to-$214M contract funds SCY-247 into Phase 2 without touching the 2029 runway, upgrading the second program from unfunded placeholder to funded option, but the investment case still rests entirely on SCY-770's unproven 2027 kidney readout.
-
4SIGHT DME Phase 3 initiated but SPECTRA 2-year data showed burden reduction falling from 78% to 61% and injection-free patients halving, tempering the DME commercial story while the wet AMD binary at 4FRONT-1 Q2 2027 remains the key catalyst; stock at $14.56 is above the deep-dive caution level.
- ACET Adicet Bio Watch
The 22-patient readout delivered 50% CRR at 12 months and a single-arm FDA pivotal path, but the efficacy gap versus autologous CD19 CAR-T is now visible, the stock closed below estimated cash, and the financing math turns dilution from a risk into a schedule — the cleaner entry may be to wait for the company to price its deal and step in alongside specialists.
- IRON Disc Medicine Watch
The company has a real mechanism and funded balance sheet, but the enterprise value already prices better-than-even odds of APOLLO success, and the sunlight endpoint failed its prespecified Phase 2 test and is powered on its best post-hoc month.
- FATE Fate Therapeutics Watch
FT819 has best-in-class manufacturing and safety but has not disclosed its pivotal endpoint response rate, the trial reads out after the cash runs out, and three named catalysts must be met before taking a position.
-
IMAgINATION proteinuria win is a second positive readout but adds only partnered milestones; TRYNGOLZA Q3 print remains the sole trigger to upgrade.
- AXSM Axsome Therapeutics Watch
AUVELITY is a real product with settled exclusivity to 2038, but at ~$10.5B enterprise value the stock already prices a successful agitation launch before a single full quarter of data; wait for Q3 results, prescription-count reconciliation, and ENGAGE topline before taking a position.
- ACIU AC Immune Watch
VacSYn week-100 met safety and immunogenicity primaries but delivered no quantified biomarker results, shifting the clinical story to a confoundable within-arm correlation and pushing Part 2 efficacy data past the Q4 2027 runway; NLRP3 hsCRP readout is now the nearest real catalyst.
-
REC-4881 shows a real signal in an orphan disease with no approved drug, but at ~$1.6B enterprise value the stock is priced for a platform whose best clinical asset it did not design and whose composition-of-matter patents expire before launch; stay on the sidelines until the FDA registrational-path update, the November CGA-IGC data, and non-dilutive Phase 3 funding are resolved.
- PALI Palisade Bio Watch
FDA IND clearance for ASCENTRA-CD is a clean execution milestone but does not advance or de-risk the ASCENTRA-UC Week 12 readout that constitutes the entire valuation; the dose discontinuity and absent U.S. patent remain unresolved.
-
24-month eGFR gap widened to 13 points with p<0.05 at three consecutive timepoints, firming the CNI-nephrotoxicity thesis, but the undisclosed NI margin and going-concern conclusion remain unresolved ahead of a mandatory raise.
- NAMS NewAmsterdam Pharma Watch
EC approval of Ubeslo and Evlarco converts European cash flows from modeled to contracted, but PREVAIL is now a post-authorization efficacy obligation making the European fallback thinner, and no U.S. NDA has been filed, keeping the Q1 2027 DSMB recommendation as the defining binary.
- TYRA Tyra Biosciences Watch
RA Capital's $200M add and Paradigm's new 5.8% stake confirm specialist money read the 57% CR as a dosing problem not a drug failure, strengthening the ownership leg of the thesis, but efficacy at 70 mg remains the only thing that can convert the rating.
-
Cash flows and 2035 patent floor are real, but the terminal value question — whether ORLADEYO's oral franchise survives a superior oral competitor — has a dated answer arriving in 2027, and there is no compensation for owning the uncertainty ahead of it.
-
FDA's Breakthrough Therapy Designation for daraxonrasib + GnP in 1L PDAC improves the regulatory path but supplies no new efficacy data, leaving launch execution and net pricing as the unresolved questions until the November commercial print.
- IDYA IDEAYA Biosciences Watch
Darovasertib's randomized PFS win is real but the valuation is carried by IDE849 and MTAP assets that face near-term, unproven tests in Western populations; no need to own it before Q4 2026 IDE849 readout.
- HRMY Harmony Biosciences Watch
A genuinely cheap and profitable business, but the entire franchise's remaining patent life hinges on a single pending court ruling due October 22, 2026, and at $41 the stock has priced that binary as already resolved favorably.
-
Dosing first EXACT patients retires execution risk but the S-1 converts the warrant overhang into registered sellable stock, and the efficacy case remains n=3 on a surrogate no regulator has validated.
- RNTX Rein Therapeutics Watch
The biology is real and the price is cheap, but the differentiating epithelial-regeneration mechanism has no significant human evidence, disclosure is selectively framed, and the true de-risking event is the full 120-patient RENEW Week-24 FVC dataset in 2028, not the Q4 2026 interim.
- NKTX Nkarta Watch
ACR Convergence November 8 oral slots confirmed with management signaling early efficacy, but below-cash cushion has closed at $3.23 and no lupus nephritis abstract; position is now a straight data bet.
- MGTX MeiraGTx Watch
The AQP1 mechanism is elegant and human-validated, but three of four 'pivotal' programs rest on failed, per-protocol, or compassionate-use datasets, and the fourth is 24 open-label patients on a questionnaire with no validated threshold; revisit on the AQUAx2 readout in Q2 2027, a sub-$9 print, or Hologen paying the $95M.
- KZIA Kazia Therapeutics Watch
Pharmacodynamics are genuinely interesting but every efficacy number comes from six unblinded patients on an active backbone with one ineligible patient providing the only complete response; a control arm is needed before taking a position.
-
First PBGENE-DMD patient dosed on schedule retires execution risk but not biology or safety risk; the HBV cure thesis still awaits NUC-withdrawal data.
-
Strong biology and productive platform, but Lineage owns only ~half the economics of a lead asset it does not control on a timeline it cannot influence; revisit only on Roche's public disclosure of intent to advance OpRegen into a controlled multicenter Phase 2/3.
-
The $150M ATM bridges the structural dilution gap and de-links launch spending from the approval-triggered warrant clock, but the Sopharma arbitration and NCE exclusivity question remain unresolved, keeping the stock uninvestable.
- GNLX Genelux Watch
Q2 burn accelerated to $9.6M against $18.7M total cash with the Phase 3 topline still guided to 2H 2026, tightening the runway squeeze but leaving the scientific thesis and watch-list stance unchanged.
- EIKN Eikon Therapeutics Watch
Resolution of the Seven and Eight licensor dispute removes a key tail risk, but accelerating burn (77% YoY) widens the dilution gap and no efficacy data has changed; the randomized melanoma interim remains the sole re-rating trigger.
-
WATCH maintained with downgraded urgency as 39.6M warrants at $2.65 are now exercisable creating a structural ceiling, NDA slipped to mid-2027, and another financing raise is likely before the key catalyst.
- ANNX Annexon Watch
ARCHER II adds Month 24 dual primary endpoint meaning Q4 2026 delivers only a DMC verdict with full data potentially in Q1 2027; catalyst diffusion and $117.8M ATM overhead keep the stock on watch despite improved GBS outlook and runway extended into 2028.
- ZURA Zura Bio Watch
Naming PMR as the third indication — where both IL-17 and B-cell arms have randomized clinical support — narrows the bear case modestly, but the BAFF contribution in HS remains unproven and Q4 2026 remains a binary with the stock more than tripled off its lows.
-
REGAL still at 78/80 events after three months of silence; readout timing now indefinite; stock at $11 with doubled downside risk vs. May; fortress balance sheet intact but premium for the binary has a time cost; watch for existing holders to consider trimming.
-
IZAR-1 Phase 3 win de-risks the PsA franchise but the de-risking event remains the Section 14 label content at BLA acceptance in late November 2026; the blinded placebo arm keeps the PsA delta unpriceable.
- IMUX Immunic Watch
Watch list maintained as runway is now explicitly bridged to late 2027 and the commercial/regulatory team is complete, but fenebrutinib, generic Aubagio, the 5% royalty stack, and dilution overhang are unchanged, and the stock at $15.48 has compressed the pre-data asymmetry considerably.
- BCAX Bicara Therapeutics Watch
Balance sheet, trial, and M&A logic remain intact and PTAB institution improves the patent overhang picture, but efficacy case is still single-arm open-label and leadership bench will be substantially new by the time the interim prints.
- RLAY Relay Therapeutics Watch
The mechanism is de-risked and the chemistry is elite, but at ~$4.35B market cap the risk/reward has already been harvested on 57- and 20-patient open-label cohorts with managed denominators; revisit on the YE2026 vascular anomaly regulatory update or a ReDiscover-2 enrollment-completion announcement.
-
Both Alzheimer's catalysts pushed to Q4 2026, VY1706 first human safety data slipped to early 2027, ATM tapped into weakness at ~$3.61, and cash down to $148.8M; proxy waiting game extended.
-
Phase 3 initiation slipped from mid-2026 to upon IND clearance due to CMC manufacturing delays, funding language softened, and no efficacy readout is expected in the next twelve months; Watch List maintained with clock reset as the next event is an IND filing, not data.
- INMB Inmune Bio Watch
Q2 brought competent execution and improved catalyst clarity (US BLA now on calendar for Q1 2027) but neither named de-risker has landed — the going-concern flag remains and the MHRA MAA submission is still ahead — so the watch stance is maintained.
- INKT MiNK Therapeutics Watch
Encouraging early safety and biomarker data from C-1300-02 are positive but uncontrolled; the binary randomized readout has slipped to early 2027, adding two quarters of dilution risk with no change in the fundamental concerns that kept this off a Buy.
- TGTX Tg Therapeutics Watch
Q2 beat and second guidance raise validate the commercial thesis, but at $46.17 — above the prior 52-week high — the easy entry has closed and the year-end SubQ Phase 3 topline remains the event worth sizing around.
- ENTX Entera Bio Watch
Despite a de-risked mechanism and strong balance sheet post-financing, the 21-patient efficacy signal, untested Phase 3 dose, primary endpoint outside FDA's qualified 24-month context of use, and 85% post-financing markup into a 26-month catalyst desert make this the wrong entry at the wrong price.
- CGEN Compugen Watch
Near-cash EV with partnered Phase 3 royalty and Gilead option provides cushion, but the owned binary (COM701 monotherapy maintenance) rests on a post-hoc subgroup and thin single-agent data in a distrusted checkpoint class, warranting a watch rather than an immediate buy.
The full record
| Category | # calls | Beat XBI | Avg return | Avg vs XBI |
|---|---|---|---|---|
| Open buy calls | 133 | 27% | -1.8% | -14.1 |
| Core | 62 | 34% | +3.9% | -13.2 |
| Speculative | 71 | 21% | -6.8% | -14.9 |
| Open avoid calls | 26 | 96% | — | +31.9 |
| Closed buy calls | 25 | 24% | +0.3% | -13 |
| Closed avoids | 19 | 63% | — | -21 |
Hypothetical editorial track record, not a managed portfolio — past performance does not guarantee future results. Not investment advice.